IRAK1 and lymphoma: As IRAK1 binding to the MyD88 adapter protein mediates toll-like receptor (TLR) immune signaling, mutation in IRAK1 is considered to be an essential driver for KS-based lymphomas, and inhibition of IRAK1/MyD88 immune signaling might serve as a potential target for drug development [31].